Boardroom Alpha
Boardroom Alpha
HURA · Additional Proxy Materials (DEFA14A) · Filed July 9, 2026

Tuhura Biosciences Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
July 9, 2026
Ticker
HURA
Accession
0001193125-26-299690
Boardroom Alpha · Filing insights

TuHURA Biosciences nominates six directors to serve through the 2027 meeting and approves share issuance; includes advisory votes.

About Tuhura Biosciences Inc
Market cap
$137M
1Y TSR
−22.5%
3Y TSR
−74.8%
Board grade
C-
Sector
Healthcare
CEO
James A Bianco
Last annual meeting: Aug 18, 2026 · View full Tuhura Biosciences Inc profile →
DEFA14A
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

 

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material Pursuant to §240.14a-12

TUHURA BIOSCIENCES, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

 

No fee required.

 

Fee paid previously with preliminary materials.

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 
 


Important Notice Regarding the Availability of Proxy Materials for

the Annual Meeting of Stockholders of

TuHURA BIOSCIENCES, INC.

To be held on August 18, 2026, at 9:00 a.m. Eastern Time

online at edge.media-server.com/mmc/p/cr7rnri9, password: tuhura2026

 

    COMPANY NUMBER
    ACCOUNT NUMBER
    CONTROL NUMBER

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting.

If you want to receive a paper or e-mail copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request as instructed below before August 4, 2026.

You are invited to attend the Annual Meeting virtually. Please visit edge.media-server.com/mmc/p/cr7rnri9 and use password tuhura2026. Have your Control Number (in the box above) available when you visit.

Please visit www.astproxyportal.com/ast/29330, where the following materials are available for view:

 

   

Notice of Annual Meeting of Stockholders

 

   

Proxy Statement

 

   

Proxy Card

 

TO REQUEST MATERIAL:   

TELEPHONE: 1-888-Proxy-NA (1-888-776-9962) or +1-201-299-6210 worldwide

 

E-MAIL: helpAST@equiniti.com

 

WEBSITE: us.astfinancial.com/OnlineProxyVoting/ProxyVoting/RequestMaterials

 

TO VOTE:

   LOGO   

ONLINE: To access your online proxy card, please visit www.voteproxy.com and follow the instructions or scan the QR code with your smartphone. You may enter your voting instructions at www.voteproxy.com until 11:59 p.m. Eastern Time the day before the meeting.

 

TELEPHONE: Call toll-free 1-800-PROXIES (1-800-776-9437) in the United States or +1-201-299-4446 worldwide from any touch-tone telephone and follow the instructions. Have this notice available when you call.

 

MAIL: You may request a card by contacting us. See “To Request Material” above.

 

1.  To elect six directors nominated to service until the 2027 annual meeting of the stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal.

  

2.  To approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of an aggregate of 1,878,287 shares of our common stock issuable pursuant to that certain Fee Letter, dated April 21, 2026, between us and Parkview Holdings One LLC.

  (01) James A Bianco, M.D.

  (02) James Manuso, Ph.D.

  (03) Alan List, M.D.

  (04) George Ng

  (05) Robert Hoffman

  (06) Craig Tendler, M.D.

  

3.  To approve, on a non-binding advisory basis, the compensation for our named executive officers.

 

4.  To approve, by non-binding advisory vote, the frequency of future advisory votes on the compensation paid to our named executive officers.

 

5  To ratify the appointment of Cherry Bekaert LLP as TuHURA’s independent registered public accounting firm for fiscal year ending December 31, 2026.

 

6.  To transact such other business as may properly come before the stockholders at the TuHURA annual meeting or any adjournment.

Please note that you cannot use this notice to vote by mail.   
From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Tuhura Biosciences Inc (HURA)

Reference

Frequently asked questions

When did Tuhura Biosciences Inc file this DEFA14A?
Tuhura Biosciences Inc (HURA) filed this Additional Proxy Materials (DEFA14A) with the SEC on July 9, 2026. The accession number assigned by EDGAR is 0001193125-26-299690.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
TuHURA Biosciences nominates six directors to serve through the 2027 meeting and approves share issuance; includes advisory votes. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Tuhura Biosciences Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Tuhura Biosciences Inc has filed under CIK 1498382, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer